Physician profile
Shawn D Bogle
NPI 1497745830
$1,605.91
in general payments reported to CMS, 2019-2025
21 companies · $91.09 in 2025
The $91.09 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $220 · 2021: $381 · 2022: $154 · 2023: $137 · 2024: $332 · 2025: $91.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $278.68 | 2019-2021 | |
| Glaxosmithkline, LLC. | $222.83 | 2021-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $154.04 | 2022-2024 | |
| Organogenesis INC. | $107.14 | 2024 | |
| Novo Nordisk INC | $78.85 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $71.43 | 2019-2023 | Eliquis |
| Biogen, INC. | $53.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $51.43 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $47.61 | 2019-2021 | |
| Edwards Lifesciences Corporation | $41.63 | 2025 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $31.93 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $31.60 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $25.26 | 2021 | |
| Amgen INC. | $23.80 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.80 | 2024 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.21 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.59 | 2023 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Bogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.